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Abstract 
 
Roles of protease-activated receptor 2 in epidermal permeability barrier 
function 
 
Se Kyoo Jeong 
 
Department of Medical Science 
The Graduate school, Yonsei University 
 
(Directed by Professor Seung Hun Lee) 
 
 
Protease-activated receptor (PAR) belongs to a subfamily of seven-
transmembrane G-protein-coupled receptors, which are distinguished by a 
unique mechanism of self-activation following specific proteolytic cleavage of 
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their extracellular domains. Recently, it was reported that the PAR-2 activator 
peptide significantly delayed epidermal permeability barrier recovery after 
acute barrier disruption in murine skin. Previous studies also showed an 
increased protease activity in atopic dermatitis lesions, and it has been 
postulated that PAR-2 activation by protease could be a pathophysiologic factor 
for atopic dermatitis. Cockroach and house dust mite allergens, both known to 
be associated with the development of asthma, allergic rhinitis, as well as atopic 
dermatitis, can activate PAR-2 and thereby affect epidermal permeability barrier 
homeostasis. In this study we investigated the effects of both allergens on the 
epidermal barrier function, as well as on epidermal calcium gradient. Both 
allergens, when topically applied on the barrier-disrupted site, increased 
protease activities in viable epidermal layers and delayed permeability barrier 
recovery and lamellar body secretion in murine skin. Topical application of 
PAR-2 specific antagonist with cockroach allergens normalized the barrier 
recovery rate, which suggests that PAR-2 activation is involved in barrier 
recovery process. Either co-application of the protease inhibitor or controlling 
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the skin surface pH at its normal acidic range, both can modulate the protease 
activity of allergens, also prevented the retardation of barrier recovery rate by 
allergens. Cockroach allergens induced intracellular calcium oscillations in 
cultured human keratinocytes in vitro through PAR-2 involved pathway, which 
was confirmed by desensitization protocol. Abnormal calcium ion distribution 
after barrier disruption was also observed in allergens-applied skin. These 
results suggest that allergens with PAR-2 activating activity can influence the 
epidermal permeability barrier homeostasis through modulation of the 
intracellular calcium concentration in stratum granulosum keratinocytes and 
modulation of protease activities with either co-application of protease 
inhibitors or controlling skin surface pH within its normal acidic levels can 
normalize this barrier retardation.  
 
Key words: aeroallergens, epidermal calcium gradient, protease-activated 
receptor-2, PAR-2 inhibitors, skin barrier 
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I. INTRODUCTION 
 
For decades, proteases were considered to have only one function, the 
degradation of proteins. The identification of the thrombin receptor in human 
platelets and vascular endothelial cells resulted in the recognition of the 
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protease as a signaling molecule, and the thrombin receptor was designated as a 
protease-activated receptor (PAR). The deduced amino acid sequence of the 
thrombin receptor also revealed that PAR was a member of the G-protein-
coupled, seven-transmembrane domain receptor family1. Since then, studies 
have led to the identification of three other subtypes of PAR. The activation of 
PARs involves a unique self-activating mechanism. Poteolytic cleavage of the 
N-terminal domain of the receptor exposes a tethered ligand domain, and this 
tethered ligand sequence binds to and activates the receptor itself, resulting in 
signaling and internalization of the receptor complex. Among the four known 
members of the PAR family, PAR-1, -3, and -4 are primarily activated by 
thrombin, while PAR-2 is preferentially activated by trypsin and other serine 
proteases, including mast cell tryptase2. 
Since the first cellular localization of PAR-2 in human keratinocytes in vitro3 
and later observations of PAR-2 in the basal, spinous, and granular layer of the 
epidermis by immunohistochemical techniques4, much effort has been invested 
to elucidate the function of PAR-2 in skin. Human skin expresses various serine 
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proteases under both physiological and inflammatory conditions5, and these 
serine proteases are associated with various homeostatic responses in skin 
disease, such as inflammation, immune responses, host defense, chemotaxis, 
cytokine expression, vascular function, tissue repair, and apoptosis6. Among 
these various cellular responses, some might be, in part, mediated via activation 
of PAR-2. For example, inflammatory mediators, such as tumor necrosis factor 
(TNF)-α, interleukin (IL)-1α, and lipopolysaccharide (LPS), upregulate PAR-2 
expression in endothelial cells7, and activation of PAR-2 leads to the release of 
prostanoids and cytokines, including IL-6 and IL-8 in epithelial cells8. Recent 
studies have also revealed the importance of PAR-2 in itching and pain 
sensation. In sensory afferent nerves, PAR-2 was shown to be associated with 
long-lasting thermal and mechanical hyperalgesia in the soma, as well as in 
visceral organs9.  
House dust mite (HDM), Dermatophagoides pteronyssinus, allergens are the 
most frequently encountered aeroallergens in temperate climates, and many 
studies have implicated HDM allergens in allergic diseases, such as asthma and 
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perennial rhinitis. In skin, HDM allergens may be an exacerbating factor for 
atopic dermatitis, an inflammatory, chronically relapsing, and extremely pruritic 
skin disease10. Recently, several studies have reported that HDM allergens have 
proteolytic activities and, specifically, that the major allergens Der p3 and Der 
p9 from HDM have serine protease activities. Previous studies have also shown 
that both the Der p3 and Der p9 allergens can activate PAR-2 in lung epithelial 
cells11. In addition, Der p1, the cysteine protease allergen from the HDM, was 
shown to activate PAR-2 in respiratory epithelial cells12. Cockroach allergens 
are another type of major aeroallergens that can also stimulate PAR-2 expressed 
in mouse lung fibroblasts13 and in human airway epithelial cells14. 
The skin, as an interface between the organism and the external environment, 
plays a major role in protecting and supporting the life it encloses. The 
functions of human skin include the maintenance of body temperature, 
recognition of the outer environment, defense against microorganisms and 
protection from harmful materials in the external environment. Among these 
important functions, defensive functions can be further classified as physical, 
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thermal, immune, ultraviolet (UV), oxidant, racial, antimicrobial and the 
permeability barrier. The epidermis is the outermost viable layer of the skin and 
expresses various proteins and other molecules that perform the above 
mentioned protective functions. Inflammatory mediators such as prostaglandins, 
eicosanoids, leukotrienes, histamines and cytokines are synthesized and 
secreted from keratinocytes and regulate the skin’s immune responses15. UV-
absorbing molecules, including melanin, trans-urocanic acid, vitamin D and C 
metabolites, and heat-shock proteins are also expressed in keratinocytes and 
play important roles in thermal and UV-barrier functions16-19. The antimicrobial 
systems in skin are primarily mediated through the surface lipids, skin surface 
acidification, iron-binding proteins and antimicrobial peptides20, 21. The 
permeability barrier function, which impedes the transcutaneous movement of 
water and other important electrolytes, is the most important defensive 
functions for terrestrial life. 
The outermost layer of the skin, the stratum corneum (SC), primarily 
mediates this permeability barrier function. SC is composed of two different 
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structural components: the corneocytes and intercorneocyte lipids. Both 
components are derived from keratinocytes through the terminal differentiation 
process. Considerable efforts have been made to elucidate the structure, 
function and biochemistry of the SC and, about two decades ago, Elias 
proposed the ‘brick and mortar model’, in which the SC is composed of flat 
cells (bricks) surrounded by a lipid matrix (mortar)22. Since then, many studies 
have been performed to elucidate the role of the SC at the organismal, 
biochemical and molecular biological levels. The corneocytes, as terminal 
differentiation forms of keratinocytes, provide structural supports for the SC 
and act as hydrating reservoirs for adequate enzymatic processes in the SC. The 
cornified envelope (CE), which encapsulates the corneocytes in SC, is a 15-
20nm-thick structure comprising defined structural proteins23. A 5nm-thick 
structure of specialized lipids, identified as the cornified lipid envelope (CLE), 
encloses the CE and this membrane-bound lipid monolayer provides 
hydrophobic interfaces between the hydrophilic surface of the CE and the 
highly hydrophobic lipid lamellae24. Recently, a detailed elucidation of the 
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component proteins of the CE and its formation has been reported25. In addition 
to these major structural domains, the corneodesmosome (CD), which 
corresponds to desmosomes in the epidermis, is another important components 
in the SC. Generally, the integrity of the SC is maintained by these intercellular 
proteins which connect to adjacent corneocytes, both in the plane of the SC 
layer and in adjacent layers. In the SC, the CD structures represent the primary 
cohesive force and they are directly related the desquamation process. These 
structures are composed of certain proteins, including desmocollin and 
desmogelin, and special protein-degrading enzymes which are presented in the 
SC and play a crucial role in the desquamation process26. Water activity and pH 
control the activity of the protease in the SC. The cholesterol sulfate/cholesterol 
ratio and protease inhibitors in the SC are also important regulators of the 
protease activity27, 28.  
The SC intercellular lipid matrix constitutes about 15% of the dry weight of 
the SC and the only continuous phase of the skin barrier. The unique lamellar, 
bilayer organization of this lipid matrix provides the structural basis for the 
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extraordinary lower permeability to water and other electrolytes through the 
SC29. The major lipid species of the SC are ceramides, fatty acids, and 
cholesterol30. Small amounts of cholesterol esters and cholesterol sulfates are 
also present in SC and both lipids play a critical role in proper structural 
organization of SC lipids and, therefore, in normal barrier function31. The 
majority of SC lipids are derived from Lamellar body (LB) and synthesized in 
the keratinocyte of the upper stratum spinosum (SS) and stratum granulosum 
(SG). At the SC-SG junction, phospholipids, sphingolipids, and other precursor 
molecules for SC lipids are extruded from the LB to the SC intercellular spaces. 
Extracellular processing of these lipid precursors provides the SC intercellular 
lipid matrix. When the epidermal permeability barrier function is compromised, 
several homeostatic responses follow. The first and most important response is 
immediate secretion of preformed LBs to the SC-SG interface. Increased 
synthesis of LBs in the granulocytes and continuing secretion to SG-SC 
interface result in a restoration of the perturbed barrier function. Synthesis of 
cholesterol, free fatty acids, and sphingolipids, which are the major constituents 
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for SC intercellular lamellae, is also increased in the epidermis to provide the 
lipid content for nascent LBs. In addition to the increase of lipid synthesis in the 
epidermis, the epidermal expression of several cytokines and DNA synthesis is 
also increased after acute disruption of barrier function, which could be an 
additional support for barrier recovery. In murine epidermis, mRNA expression 
of tumor necrosis factor (TNF)-α, interleukin (IL)-1α, IL-1β and granulocyte 
macrophage-colony-stimulating factor (GM-CSF) are elevated after barrier 
disruption. 
For a complete recovery of epidermal permeability barrier function, both the 
corneocytes of the SC intercellular lipids need to be replenished into the barrier-
damaged skin site. While a great deal of studies have been reported on the 
regulation of lipid synthesis in the stratum granulosum after barrier disruption, 
relatively little is known about the regulation of keratinocyte differentiation 
after barrier disruption and its role in barrier homeostasis. Peroxisome 
proliferator-activated receptor (PPAR) and liver X receptor (LXR) belong to a 
subset of the nuclear hormone receptor superfamily (class II receptors), which 
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need retinoid X receptor (RXR) as a heterodimerizing factor for their 
activation32. PPAR and LXR are ligand-activated transcriptional factors that 
regulate the expression of target genes involved in many cellular functions 
including cell proliferation, differentiation and immune/inflammation responses. 
Along with the fibrate hypolipidemic agents, a large number of endogenous 
fatty acids and fatty acid metabolites can activate PPAR. Several oxysterols, 
including cholesterol, can activate LXR33. Activation of PPAR and LXR in 
epidermis, induced various cellular responses including the promotion of 
keratinocyte differentiation and alleviation of epidermal hyperproliferation, as 
well as the reduction of epidermal inflammation. Recently, it was also shown 
that topical application of PPAR or LAX activator on barrier-disrupted skin 
improves epidermal permeability barrier recovery, inducing an increase of 
epidermal lipid synthesis and LB secretion34. Since endogenous lipids produced 
in the keratinocyte can activate PPAR or LXR, and, in turn, regulate lipid 
metabolism of the keratinocyte, these receptors are currently referred to as 
'liposensors' in keratinocytes, and considered major players connecting lipid 
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metabolism and keratinocyte differentiation. 
In 1985, Menon et al. reported that an epidermal calcium gradient with low 
calcium concentrations in the basal, proliferating layers, and a progressively 
higher concentration as one proceeds to the outer differentiated layers, i.e. the 
SG35. Several years later, it was suggested that this epidermal calcium gradient 
plays a crucial role in skin barrier function36. Acute barrier disruption with 
either acetone treatment or repeated tape stripping induced an immediate, 
marked decrease of intracellular calcium concentrations in the SG. The calcium 
levels in the SG then progressively normalized in parallel with barrier recovery 
over 24 hours37. Recently, Elias et al. reported the relationship of barrier 
function and the reappearance of the epidermal calcium gradient after acute 
barrier disruption38. Immediate application of a vapor-permeable membrane on 
the barrier-disrupted skin provided an artificial permeability barrier and 
accelerated epidermal calcium gradient formation. While the exposure of 
barrier-disrupted skin to a cold environment retarded both the barrier recovery 
and calcium gradient formation, vapor-permeable membrane application with 
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cold exposure resulted in significant calcium gradient formation after three 
hours, without barrier recovery. With these results, it can be postulated that 
barrier status dominantly regulates the formation of the epidermal calcium 
gradient and calcium gradient formation or maintenance is achieved though 
passive, ATP-independent processes. Many studies exploring the relationship 
between permeability barrier homeostasis and epidermal calcium ions have 
been reported. Sonophoresis and iontophoresis are both used for increasing the 
delivery of drugs and other bioactive materials across the SC and were shown 
to decrease the calcium concentrations in the upper epidermis. While the 
sonophoresis or iontophoresis-treated skin showed no changes in TEWL, 
increased secretion and synthesis of LB were observed in both skin layers39-41. 
Since the secretion of LB from the SG and consequent accumulation of lamellar 
materials at the SC-SG junction is a hallmark for barrier homeostatic responses 
after barrier disruption, these results showed that the regulation of LB secretion 
is mediated by calcium ions in the SG. Recently, it has been reported that 
several agonists and antagonists for G-protein-coupled receptors (GPCRs) 
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expressed in keratinocytes, such as the γ-aminobutyric acid receptor (GABA)42, 
the P2X purinergic receptor43, the N-methyl-D-aspartic acid (NMDA) type 
glutamate receptor44, the β2-adrenergic receptor45 and the histamine receptor46, 
have accelerating or delaying effects on barrier recovery after acute barrier 
disruption. Since the major signaling molecules for GPCRs include intracellular 
calcium ions, it can be concluded that the change of intracellular calcium ion 
concentration is a major signal for permeability barrier homeostasis. In addition 
to the GPCR activation-related calcium modulation, it was also shown that 
topical application of calcium chelating agents onto normal skin induced the 
barrier homeostatic responses, including loss of the epidermal calcium gradient 
and LB secretion47. Topical application of glycolic acid, which does not induce 
any changes in TEWL in normal murine skin, significantly increased LB 
secretion48, 49 and an in vitro study using cultured keratinocytes suggests that 
glycolic acid could lower the calcium ion concentration, at least in part, through 
its chelating effects on cations, such as calcium ions. 
Disturbance of the epidermal barrier results in increased penetration of 
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microbes and allergens, which increases the risk of sensitization to allergenic 
molecules and non-allergenic inflammatory reactions. It is well known that the 
skin barrier function is damaged in AD patients, both in acute eczematous 
lesions and in clinically unaffected skin50. When the permeability barrier is 
disrupted, finely regulated homeostatic responses are initiated to restore the 
normal barrier function. Briefly, immediate secretion of pre-formed LBs into 
the SG-SC interface occurs, followed by a rapid formation of LBs in the upper 
SG. Increases of epidermal cytokines and DNA synthesis are also induced in 
homeostatic reactions51. Recently, Hachem et al. reported that topical 
application of PAR-2 activator peptides (APs) on barrier-disrupted skin 
significantly delayed the barrier recovery rate and interfered with the 
aforementioned homeostatic responses52. Since the HDM or cockroach 
allergens also have PAR-2 activating effects, the topical application of either 
allergen on barrier-disrupted skin can also result in delayed barrier recovery rate. 
To address this issue, experimental disruption of barrier function, using 
repeated tape stripping on hairless mice or human volunteers, was performed, 
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and barrier recovery rate was measured. In addition, in order to confirm 
whether the effects of allergens on barrier function are due to the proteolytic 
activity of the allergens and consequent activation of PAR-2, the impact on 
barrier recovery of co-application of allergens and a serine protease inhibitor 
was also evaluated. 
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II. MATERIALS AND METHODS 
 
1. Materials  
  House dust mite extracts and German cockroach extracts were prepared 
according to a protocol reported previously53. Briefly, 30 g of frozen dust mites 
and German cockroaches were pulverized in liquid nitrogen and the defatted 
samples in 200 ㎖ of a 1:1 volume of ethyl ether/ethyl acetate were extracted 
with slow stirring at 4℃ overnight in 100mM phosphate buffered saline 
solution (pH 7.4). The extracts were then centrifuged at 10,000g for 30 minutes 
at 4℃and the supernatants were finally filtered through a 0.22 ㎛ filter. The 
endotoxin contents, determined by using E-toxate assay, were negative for both 
extracts. Total protein quantity in both extracts, as evaluated by Bradford assay 
reagent (Bio-Rad, Hercules, CA, USA), were 2.89 ㎎/㎖ and 3.0 ㎎/㎖ for 
cockroach extract and house dust mite extract, respectively. The protease 
inhibitor RWJ-50,353 was purchased from Merck KgaA (Darmstadt, Germany). 
Trypsin type IX-S, the reference protease, was purchased from Sigma Co. (St. 
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Louis, MO, USA) and the protease activity of both allergens was measured 
using an EnzCheck protease assay kit (Molecular Probes, Inc., Eugene, OR, 
USA) according to the supplier’s recommendation. Total reaction volume for 
the assay was 200 ㎕ and pH-insensitive green fluorescent BODIPY-FL 
conjugated-casein was used as a substrate. BODIFY-FL conjugated casein 
solution (10 ㎍/㎖) was prepared with 10mM Tris-HCl buffer solution (pH7.8), 
containing 0.1mM sodium azide. Preparation and dilution of the enzyme 
solution or allergen extracts were performed with phosphate saline solution 
(PBS) (pH 7.4). In 96 well plate (OptiPlate 96F, Perkin Elmer, Boston, MA, 
USA), 100 ㎕ of substrate solution and 100 ㎕ of enzyme solution or allergen 
extracts were added to each well. The reaction mixture was incubated for 1 hour 
at 37℃, protected from light. The fluorescence was measured by the HTS 
multi-label reader (Perkin Elmer, Boston, MA, USA), with an excitation 
wavelength of 485 nm and an emission wavelength of 530 nm. All other 
chemicals used were of analytical grade.  
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2. Human studies 
Five healthy male subjects (ages 27-35 yrs) and one healthy female subject 
(age 29 yrs) without any history of atopy or dermatological disease volunteered 
for this study. All of the subjects registered negative in the dust mite patch test 
and participated in this study after providing written informed consent. The 
study was approved by the institutional review board of Yonsei University 
College of Medicine. After resting for at least 30 min in a temperature- 
(22±2℃) and humidity (40 – 50%) -controlled room, basal transepidermal 
water loss (TEWL) was measured at the volar forearm using Tewameter TM210 
(Courage & Khazaka GmbH, Cologne, Germany) and acute disruption of the 
epidermal permeability barrier was performed by repeated tape-stripping using 
3M cellophane tape until the TEWL value reached about 35 – 40 g/m2/hr. After 
barrier disruption, 150㎕ of house dust mite extract was applied to the barrier-
disrupted site for 10 minutes. At 3 and 6 hours following barrier disruption, 
TEWL was measured and the barrier recovery rate was calculated. Phosphate 
buffered saline solution (pH 7.4), which was used for preparing dust mite and 
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cockroach extract allergens, was also topically applied to barrier disrupted skin 
site as a control group.  
 
3. Animals 
Female hairless mice Hr-/Hr- were purchased from the animal laboratory of 
Yonsei University and used at 8- to 12-weeks old. All animals were kept under 
controlled humidity (40-50%) and temperature (22±2℃), and were fed a 
standard diet and water ad libitum. After anaesthetizing the mice using 
intraperitoneal injection of 4% chloral hydrate, basal TEWL was measured at 
both flanks and the permeability barrier was disrupted by repeated tape 
stripping. Immediately after barrier disruption, 150㎕ of extracts were topically 
applied to the barrier-disrupted site for 10 minutes. Phosphate buffered saline 
solution (pH 7.4), which was used for preparing dust mite and cockroach 
extract allergens, was also topically applied to barrier disrupted skin site as a 
control group. At 3 and 6 hours following barrier disruption, TEWL was 
measured and barrier recovery was calculated. 
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4. In situ zymographic measurement of protease activity in epidermis 
The proteolytic activity within the epidermis was examined by in situ 
zymography. Either cockroach extracts or vehicle was topically applied to 
normal or barrier disrupted skin site of hairless mice and skin biopsies were 
taken. Frozen sections (5㎛ thickness) were rinsed with washing solution (1% 
Tween 20 in deionized water) and incubated at 37℃ for 1 hours with 250㎕ of 
BODIFY-Fl-casein (1㎍/㎖) in deionized water (2㎕/㎖). After incubation, 
sections were rinsed with washing solution and observed under confocal 
LASER microscope (Zeiss LSM 500, Carl Zeiss Microimaging Inc., 
Thornwood, NY, USA) at an excitation wavelength of 485nm and an emission 
wavelength of 530nm. 
 
5. Synthesis of PAR-2 specific inhibitors 
 Piperazine was quantitatively introduced to the 2-chlorotritylchloride (CTC) 
(0.3–0.5 mmol/g) resin under diisopropylethylamine (DIPEA) in N-
methylpyrrolidone (NMP) and then the general protocol of benzotriazole-1-
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yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP)- 
mediated coupling method afforded resin-bound (1). After cleavage with 1% 
TFA solution, (1) was obtained in yields of 92–95%.  
Isovaleric acid was introduced to the remaining free amine of (1) with the 
general protocol of BOP-mediated coupling method and then (2) was isolated 
by flash chromatography. After de-protection of Boc group in (2), the final 
product (3) was precipitated in cold ether. 
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Figure 1. PAR-2 inhibitor synthesis. Reagents and conditions: (a) DIPEA, 
NMP; (b) BOP, 1-hydroxybenzotriazole (HOBt), NMP (c) 1%TFA, 
1%Triisopropylsilane in DCM; (d) BOP, HOBt, NMP; (e) silica gel; (f) 
25% TFA in DCM (g) ether. 
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6. Neutral lipid deposition in stratum corneum 
 Skin biopsies of hairless mice were taken at 3 and 6 hours after barrier 
disruption, and Nile red staining was performed to observe the neutral lipids 
distribution in the stratum corneum. 4mM Nile red solution (100㎍/㎖ and 
75% glycerol) was applied to cryostat sections (5㎛ thickness) and specimens 
were examined by confocal LASER scanning microscopy (Bio-Rad MRC 600 
mounted on a Zeiss LSM510 inverted microscope). Excitation and emission 
wavelengths were 488nm and 514nm, respectively. At least five sections were 
observed to find common features and representative sections were selected.  
 
7. Cell culture and [Ca2+]i measurement 
 Neonatal human epidermal keratinocytes (Cascade Biologics, Portland, OR, 
USA) were grown in EpiLide Medium supplemented with supplied growth 
factors (Cascade Biologics). Cells were grown at 37℃ in a humidified 
atmosphere of 5% CO2 and 95% air. For dye loading, the cells were seeded on 
polylysine-coated cover slips at 4X106 cells/mL per 60mm dish and were used 
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at 80% confluency. The composition of the extracellular physiologic salt 
solution (PSS) used for measuring the [Ca2+] change was as follows: NaCl, 140 
mmol/L; KCl, 5 mmol/L; MgCl2, 1 mmol/L; CaCl2, 1 mmol/L; HEPES, 10 
mmol/L; and glucose, 10 mmol/L titrated to pH 7.4 with NaOH. Ca2+-free 
media was Ca2+-free PSS that contained 1 mmol/L EDTA and 1 mmol/L 
ethyleneglycol-bio-(β-aminoethylether)-N,N,N’,N’-tetra-acetic acid. Cells were 
incubated for 2 hours in PSS containing 5 µmol/L fura-2-acetoxymethyl ester in 
the presence of Pluronic F-127 to enhance dye loading. Changes in [CA2+]i 
were measured by means of fura-2 fluorescence, with excitation wavelengths of 
340 nm and 380 nm, respectively, and an emission wavelength of 510 nm at 
room temperature. Background fluorescence was subtracted from the raw 
signals at each excitation wavelength before calculating the fluorescence ratio 
as follows:  
Ratio = F340/F380 
 The emitted fluorescence was monitored with a CCD camera (Photon 
Technology International Inc., Lawrenceville, NJ, USA) attached to an inverted 
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microscope.  
 
8. Electron microscopy 
After biopsy, skin samples were fixed in modified Karnovsky’s fixative 
overnight, and post-fixed with 0.25% ruthenium tetroxide, containing 1.5% 
potassium ferrocyanide, as described previously54. After further counterstaining 
with lead citrate, ultrathin sections (LEIKA UCT, LEIKA, Lussloch, Germany) 
were examined under an electron microscope (Hitachi H7600, Hitachi, Tokyo, 
Japan) operating at 80kV. LB density and secretion were assessed visually in 
randomly selected photographs without knowledge of the experimental 
treatment groups.  
Calcium ion-capture cytochemistry was performed to investigate the change in 
epidermal calcium ion distribution in murine skin. After biopsy, the specimens 
were finely minced and immersed in an ice-cold fixative, which contained 2% 
glutaraldehyde, 2% formaldehyde, 90mM potassium oxalate and 1.4% sucrose 
(pH 7.4). After overnight incubation, specimens were post-fixed in 1% OsO4 
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containing 2% potassium pyroantimonite for 2 hours. After embedding in Epon-
epoxy resin mixture, ultrathin sections (LEIKA UCT, LEIKA, Lussloch, 
Germany) were examined under the electron microscope (Hitachi H7600, 
Hitachi, Tokyo, Japan) operating at 80kV. At least 10 electron micrographs were 
taken for each specimen, and representative pictures were taken. 
 
9. Statistical analyses and data presentation 
 Statistical analyses were performed using InStat 3 software (GraphPad 
Software Inc., San Diego, CA, USA). Non-paired two-tailed student’s t-test was 
performed to calculate the statistical significance. Values are given as means ± 
SEM. 
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III. RESULTS 
 
1. Topical application of allergens significantly delayed epidermal 
permeability barrier recovery in both human and murine skin 
In order to assess the effects of house dust mite allergens (HDMA) on 
epidermal permeability barrier homeostasis, human volunteers without any skin 
disease and having no history of atopy were adopted. The permeability barrier 
of the volar forearm was acutely disrupted by repeated tape stripping and 
HDMA were topically applied to the barrier-disrupted skin site. At 3 hours after 
barrier disruption, the barrier recovery rate for the HDMA-applied skin showed 
a significant decrease compared to the vehicle-treated skin. At 6 hours, HDMA-
applied skin showed a slightly lower recovery rate than vehicle-applied skin, 
but statistical significance was not observed (Fig 2A). 
The inhibitory effect of HDMA on epidermal permeability barrier recovery 
was also observed in murine skin. At 3 hours after barrier disruption, barrier 
recovery for the HDMA-applied site was significantly delayed compared to the 
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vehicle-treated site (Fig 2B). Application of cockroach extract also significantly 
delayed barrier recovery at 3 and 6 hours (Fig 2C). In order to verify that the 
inhibitory effect of allergens on barrier recovery is due to the activation of 
protease activated receptor (PAR)-2 in epidermis, PAR-2 specific inhibitor was 
synthesized and applied to the barrier disrupted skin site55. Single application of 
PAR-2 inhibitor resulted in a significant acceleration of barrier recovery rate at 
3 hours after barrier disruption, compared to either cockroach-only application 
or both inhibitor and cockroach application. Simultaneous application of PAR-2 
specific inhibitors with cockroach allergen also accelerated the barrier recovery 
rate than cockroach-only application at 3 hours after barrier disruption, but no 
statistical significance was observed (Fig 2D).  
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Figure 2. Topical application of house dust mite (HDM) allergens on 
barrier disrupted skin significantly delayed barrier recovery in human 
skin (A). Retardation of barrier recovery was also observed when mite 
allergens (B) or German cockroach allergens (GCA) (C) were applied to 
murine skin. Repeated tape stripping was performed on both flanks of 
hairless mice and the barrier function was evaluated by measuring 
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transepidermal water loss (TEWL) value using TEWAmeter TM210 
(Courage & Khazaka, Köln, Germany). HDMA and GCA were prepared 
according to the previous report, and the protein concentration was 
3.0㎎/mL and 2.84㎎/mL for HMDA and GCA, respectively. (n=6, *: p<0.05, 
**: p<0.01) 
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The neutral lipids distribution after barrier disruption, visualized by Nile red 
staining, also showed delayed recovery of lipids in the stratum corneum for the 
cockroach applied-site compared to the vehicle-applied site at 3 and 6 hours 
after disruption (Fig 3). 
 
 
Figure 3. Topical application of cockroach allergens on barrier disrupted 
skin caused decreased neutral lipid deposition in the stratum corneum. Nile 
red staining (X200) 
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In order to clarify whether the decrease of SC intercellular lipids in cockroach 
extract-applied skin was due to the change in lamellar body secretion, we 
examined the LB secretion system using electron microscopy. While there were 
no significant differences in the number of LBs in the SC-SG interface between 
control skin and cockroach extract-applied skin immediately after barrier 
disruption, a statistically significant decrease was observed in the cockroach 
extract-applied site at 3 hours after barrier disruption (Fig 4A). However, 
synthesis of LBs in the upper SG, represented by the number of LBs in the 
upper SG, showed no changes after cockroach extract application (Fig 4B). The 
above results suggest that the retardation of barrier recovery in cockroach 
extract-applied skin is in part due to the decreased secretion of LBs after barrier 
disruption.  
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Figure 4. Topical application of cockroach allergens delayed Lamellar body 
(LB) secretion after acute barrier disruption. At 3 hours after barrier 
disruption, the number of secreted LB at the SG-SC junction significantly 
decreased in cockroach allergen-applied skin compared to vehicle-treated 
skin (A). The number of LBs in the upper SG, which represents the LB 
synthesis after barrier disruption, did not show any significant changes 
after cockroach allergen application (B). Data represents means ± SEM. 
(n>7, *: p<0.05) 
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2. Topical application of cockroach allergens increased proteolytic activities 
in epidermis in vivo 
 In order to clarify whether topical application of cockroach extracts increased 
the proteolytic activities in vivo, protease activity in epidermis was examined 
using in situ zymography. An increase of proteolytic activity was observed in 
suprabasal layer after acute barrier disruption (Fig 5B), compared with control 
skin (Fig 5A). These results are consistent with previous observations of an 
increase of proteolytic activity in epidermis after barrier disruption. In addition, 
topical application of cockroach extracts after barrier disruption significantly 
increased the protease activity through the whole epidermis (Fig 5C), which 
suggested that increased proteolytic activity is a possible mediator for delayed 
barrier recovery.  
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Figure 5. Topical application of cockroach allergens increases epidermal 
proteolytic activity in barrier disrupted skin. Acute barrier disruption was 
performed in hairless mice skin and cockroach allergen was topically 
applied. SC: stratum corneum. In situ zymography (X400) 
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3. Co-application of protease inhibitors with allergens normalized barrier 
recovery 
  To investigate whether the inhibitory effect of both allergens on barrier 
recovery were due to their proteolytic effects, the proteolytic activities were 
measured using a fluorescence-tagged substrate for protease. A serine-protease-
like proteolytic activity was observed for both extracts, and the cockroach 
extract showed much higher activity than the HDMA. The proteolytic activity 
was significantly reduced in the presence of the protease inhibitor RWJ-
50,35356, which confirmed that the activities were primarily due to the protease 
activities in both allergens (Fig 6A). When the RWJ-50,353 was co-applied 
with cockroach extracts on barrier-disrupted skin, the recovery rate was 
significantly accelerated, compared to the extracts only-applied site (Fig 6B). 
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Figure 6. Trypsin type IX-S (Sigma, St. Louis, MO) was used as a reference 
protease and relative protease activities of the extracts were measured 
using an EnzCheck® Protease assay kit (Molecular Probes, Eugene, OR) 
according to the manufacturer’s protocol, with a slight modification. 
Protein concentrations of cockroach and mite extracts were 2.84㎎/mL and 
3㎎/mL, respectively, and the concentration of PPACK, a serine protease 
inhibitor (RWJ-50,353, Merck Bioscience, Darmstadt, Germany) was 
5㎎/mL. The data represent the averaged result of triplicate experiments 
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(A). Topical application of PPACK (RWJ-50,353, Merck Bioscience, 
Darmstardt, Germany) significantly accelerated the barrier recovery rate 
of GCE-applied skin , while PPACK only did not (B). 100mM Tris buffer 
solutions with indicated pHs were used for measuring the protease 
activities. Higher activity in pH 4.2 medium than in pH 5.5 medium may be 
due to the change of fluorescence intensity induced by the lower pH. The 
data represent the averaged result of triplicate experiments (C). Topical 
application of Tris buffer (100mM, pH 5.5) prior to GCE application 
accelerated the barrier recovery rate more than that of the Tris buffer pH 
7.0-applied skin. After barrier disruption using the repeated tape stripping 
method, Tris buffer solution of pH 5.5 and pH 7.0, respectively, was applied 
to the barrier disrupted skin for 15 minutes and GCE was then applied to 
the same site (D). Data represents means ± SEM. (n>6, *: p<0.05)  
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4. Acidic skin condition after barrier disruption normalized barrier 
recovery 
Skin surface pH, which is slightly acidic under normal conditions, increases 
after acute barrier disruption and progressively returns to its normal range with 
barrier recovery57. Since the optimal pH condition for cockroach extracts was 
about pH 7.0 (Fig 6C), we tried to examine the effects of immediate 
acidification of the barrier-disrupted site on the inhibitory action of cockroach 
extracts for barrier recovery. When the acidic buffer solution (100mM Tris 
buffer solution, pH 5.5) was co-applied with cockroach extracts to barrier-
disrupted skin, the recovery rate was accelerated, compared to that of the 
neutral buffer solution (100mM Tris buffer solution, ph 7.0) co-applied site (Fig 
6D).  
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5. Cockroach extracts induced [Ca2+]i oscillations in cultured human 
keratinocytes 
In a previous study, we observed that cockroach extract induced a baseline 
type of [Ca2+]i oscillation in a dose-dependent manner in human airway 
epithelial cells1414. The [Ca2+]i oscillations induced by cockroach extracts were 
due to the activation of PAR-2 in epithelial cells, which was verified by 
desensitization protocols. In cultured human keratinocytes, which also express 
PAR-2, similar results were obtained and treatment with cockroach extracts 
induced [Ca2+]i oscillations. The frequency of the oscillations was dependent on 
the concentration of cockroach extract, but the amplitude of the spikes was 
unaffected by the cockroach extract concentration, a result similar to that in our 
previous report1414 (Fig 7A, B). In order to verify whether PAR-2 activation is 
involved in [Ca2+]i oscillations caused by cockroach allergens treatment, we 
used desensitization protocols. After desensitizing the cockroach allergen-
responsive receptors by repeated simulation with high concentrated cockroach 
allergens (270 ㎍/㎖), they showed no response to PAR-2 specific activator 
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peptides. However, no effect on the Ca2+ signal evoked by sphingosine-1-
phosphate, which is a different subclass of GPCR activator, was observed in 
cockroach allergen-desensitized cells (Fig 7C). Finally, Fig 7 D shows that 0.5 
mM soybean trypsin inhibitor reversibly inhibited the response to cockroach 
allergens. These results suggest that PAR-2 is involved in cockroach allergen-
induced [Ca2+]i oscillation in keratinocytes.  
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Figure 7. [Ca2+]i oscillation induced by various concentrations of cockroach 
allergens ranging from 1 to 10 µg/mL.  
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6. Topical application of cockroach extracts on barrier-disrupted skin 
alters the epidermal calcium gradient 
 Several reports suggested a close relationship between activation of G-protein-
coupled receptors and epidermal permeability barrier homeostasis, through the 
modulation of intracellular calcium concentration46,58. Since PAR-2 belongs to a 
family of G-protein-coupled seven transmembrane domain receptors, we 
postulated that the inhibitory effects of cockroach allergens on barrier recovery 
may be due to the change in intracellular calcium concentration. Using calcium-
ion capture cytochemical staining, we observed changes in the epidermal 
calcium gradient after barrier disruption by electron microscopy. In normal 
tissue, a well-defined epidermal calcium gradient was seen, with low levels of 
calcium ions in basal and spinus layers and increased depositions in the 
granular layer (Fig 8A). In the vehicle-applied skin, nearly complete loss and 
partial restoration of the calcium gradient was seen at 3 and 6 hours after barrier 
disruption, respectively (Fig 8B, C). In cockroach extract-applied skin, however, 
increased deposition of calcium ions in granular layers was observed at 3 and 6 
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hours after barrier disruption, compared to the vehicle-treated skin (Fig 8D, E). 
These results suggest that the inhibitory effects of cockroach extract on barrier 
recovery were possibly due to the modulation of intracellular calcium ions in 
granular layers.  
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Figure 8. Calcium ion distribution in epidermis after barrier disruption 
was observed by calcium-ion capture cytochemical staining. Control skin 
showed a normal epidermal calcium gradient across the epidermis (A). In 
the vehicle-applied skin, loss of calcium gradient was seen at 3 hours after 
barrier disruption (B) and partial recovery was observed after 6 hours (C). 
In cockroach allergens-applied skin, increased deposition of calcium ions in 
granular layers was observed at 3 hours (D) and 6 hours (E) after barrier 
disruption. (X5,000) 
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IV. DISCUSSION 
 
Currently, several skin diseases are known to show a defect in epidermal 
permeability barrier function as a major or minor pathophysiologic factor. 
While the most representative ones include atopic dermatitis (AD) and psoriasis, 
other skin diseases caused by genetic defects in lipid metabolism are also 
accompanied by barrier defects. Recessive X-linked lamallar ichthyosis (RXLI) 
is one of such disease. It is caused by a deficiency in the enzyme steroid 
sulfatase and leads to an accumulation of cholesterol sulfate and a reduction of 
cholesterol. The abnormality of cholesterol sulfate/cholesterol balance results in 
an altered lipid organization and consequent abnormality in the structural 
organization of the intercorneocyte lipid lamellae59. Cholesterol sulfate is also 
known to affect other biological processes such as protease activity in the SC, 
which results in abnormal desquamation in the RXLI27. In addition to the 
inhibitory effects on protease in the SC, cholesterol sulfate also acts as an 
activating factor for the eta isoform of protein kinase C (PKC eta). PKC eta is a 
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subtype of novel PKC and, in the keratinocyte, is closely associated with cell 
cycle arrest and differentiation60. It can, therefore, be postulated that cholesterol 
sulfate is also related to the differentiation of epidermal keratinocytes. Other 
genetic skin diseases, including Netherton syndrome61, characterized by defects 
in proteolysis, and type 2 Gaucher disease, exhibiting defects in β-
glucocerebrosidase, involve skin barrier abnormalities as a pathologic outcomes.  
While various pathogenic factors are suggested for AD, impaired barrier 
function is currently considered an important one. Atopic dry skin displays 
impaired barrier function, indicated by an increased transepidermal water loss 
and lowered water-binding capacities. Significant decreases in SC ceramide62, 
especially in ceramide 1 (CER EOS) levels is reported in AD skin63. Bouwstra 
et al. suggested that the ceramide 1 in SC intercellular lipids plays a dominant 
role in the formation of proper molecular organization64. In addition, Pilgram et 
al. reported that the abnormal lipid organization in the SC of AD patients 
resulted from the decrease of ceramide 1 and suggested that the impaired barrier 
function of AD skin was, at least in part, due to this structural change65. 
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Recently, we have reported a structural property of a physiologic lipid mixture 
containing a pseudoceramide, which showed a close similarity to that of SC 
intercellular lipids29. Since the structural property of lipids can affect the 
epidermal permeability barrier function, it might be beneficial to barrier 
function to use the physiologic lipid mixture on the barrier-disrupted skin. 
  The decrease of ceramides in AD patients is linked to an increased expression 
of sphingomyelin deacylase, which converts the sphingomyelin to free fatty 
acids and sphingosylphosphorylcholine66. In normal skin, epidermal 
sphingomyelin is catalyzed by sphingomyelinase to produce ceramide, but in 
AD skin, extraordinary sphingomyelin deacylase activity is presented. Recently, 
the existence of another novel enzyme, termed as glucosylceramide deacylase, 
has been reported in AD skin lesions. In normal skin, glucosyl-ceramide, 
secreted into the SC through LBs, is catalyzed by β-gluco-cerebrosidase to 
produce ceramide. In AD skin, however, glucosylceramide is catalyzed by this 
novel enzyme to produce glucosylsphingosine67. With this enzymatic 
abnormality, ceramide level is down regulated in AD skin, and permeability 
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barrier function is incompetent. Altered ceramide metabolism in AD skin also 
induces a decrease in sphingosine, which is produced from ceramide by 
ceramidase in the SC. Since sphingosine is known to have potent antimicrobial 
activities on Staphylococcus aureus at physiologic levels, down regulation of 
sphingosine is one of the reasons for the vulnerability of AD patients to S. 
aureus colonization68.  
In addition to the abnormalities in lipid processing metabolism, genomic 
defects can also affect the barrier abnormalities in AD. Recently, it was 
reported that there is a lack of differentiation-specific gene expression in the 
keratinocytes in AD skin lesions. Using a large-scale DNA microarray Sugiura 
et al. showed a significant decrease of mRNA expression of filaggrin and 
loricrin in AD skin69. More recently, loss-of-function mutations for 
keratinocyte-differentiation related-genes encoding filaggrin are observed in 
AD patients and suggested as an important risk factor in AD70. As seen in 
another recent report showing filaggrin gene mutations in several families of 
ichthyosis vulgaris71, defects in adequate filaggrin formation in terminal 
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differentiation of epidermal keratinocytes results in abnormal keratinization of 
skin. Filaggrins are crucial proteins for terminal differentiation of the epidermal 
keratinocytes, which form a skin barrier with the SC intercellular lipids. In 
addition, pyrrolidone carboxylic acid (PCA), as a major component of the 
natural moisturizing factors (NMF) in skin, is primarily produced from filaggrin 
proteins in the SC and plays a vital role in maintaining the hydration of the SC. 
It was also previously reported that filaggrin mutation is associated with the dry 
skin phenotype, which is characterized by a decrease of the NMF components 
in skin72. Mutations of filaggrin genes result in abnormal corneocyte structure 
and impaired barrier function, leading to skin that is more vulnerable to the 
penetration of exogenous allergens than normal skin. Along with the 
abnormalities in lipid metabolisms, these findings suggest that both the bricks 
and the mortar have defects in AD skin, and consequent impairment of 
epidermal barrier function is an important pathophysiologic factor for AD73. 
 The results of this study suggest that HDM or cockroach allergens can be 
aggravating factors for epidermal permeability homeostasis of barrier function 
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perturbed skin. Atopic dermatitis (AD) is an inflammatory, chronically 
relapsing and extremely pruritic skin disease. Whether HDM allergens or 
cockroach allergens have a direct pathophysiologic role in AD remains 
controversial74, but a lot of studies suggest that HDM sensitization is more 
common in patients with AD than in non-atopic controls75-77. The immunologic 
evidence underlying the contribution of HDM allergens to the pathogenesis of 
AD include the presence of local antigen, antigen-specific T lymphocytes, 
relevant cytokine production, and effector cells including eosinophils in lesional 
skin78. In addition to immunologic disturbance, another characteristic feature of 
AD skin lesions is perturbation of epidermal permeability barrier function. The 
defect in permeability barrier function in AD skin may be caused by a decrease 
in SC intercellular lipids, especially ceramide species, and flawed molecular 
organization of intercellular lipids65. Impaired differentiation, represented by 
abnormal expression of cornified envelope and keratins, is also involved in the 
defective barrier function of AD79. In normal skin, aeroallergens do not easily 
reach antigen-presenting cells, such as dendritic cells in subepithelial tissues, 
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owing to the effective barrier function of stratum corneum, and tight junctions 
between viable epidermal cells and basal lamina. A defective permeability 
barrier in AD skin lesions, however, leads to an increased penetration of 
environmental allergens into skin, which initiates immunologic reactions and 
aggravates consequent allergic inflammations, steps crucially involved in the 
pathogenesis of AD. Recently, two common loss-of-function mutations in the 
gene encoding filaggrin have been reported70, 71. Since the filaggrin protein 
plays a crucial role in maintaining the epidermal barrier function, these results 
suggest an important role of the skin barrier in preventing allergic 
sensitization80.  
  Interestingly, several reports have suggested that HDM allergens could also 
interfere with the epidermal barrier function81. Even in normal skin, 
simultaneous application of HDM allergens with sodium dodecyl sulphate 
(SDS) induced a highly pronounced increase in TEWL, compared to HDM 
allergens- or SDS-only applied skin82. Since the application of SDS results in 
the disruption of skin barrier function83, these results suggest that HDM 
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allergens can be an aggravating factor for epidermal permeability barrier 
function for compromised skin, an idea consistent with our result. When barrier 
disrupted skin is exposed to HDM allergens, the barrier function is perturbed 
further. Consequently, additional allergens can more easily penetrate the skin, 
perpetuate barrier disruption and result in continuous eczematous lesions in AD.  
  It is well known that skin surface pH, which ranges from pH 4.5 to pH 5.5 in 
humans, is slightly acidic compared to the normal physiologic pH84. SC acidity, 
or the “acid mantle” is currently considered to be crucial for establishing the 
epidermal permeability barrier, as well as for producing the epidermal 
antimicrobial barrier and controlling SC integrity and cohesion. Various 
endogenous and/or exogenous pathways are currently suggested for acidifying 
the pH of the SC. Endogenous factors influencing SC acidification include the 
generation of free fatty acids from phospholipid hydrolysis catalyzed by 
secretory phospholipase A2 (sPLA2) and the sodium-proton antiporter-1, NHE1, 
which is expressed in the outer, nucleated layers of the epidermis85. Exogenous 
mechanisms include the generation of free fatty acids by bacterial lipase, free 
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fatty acids derived from sebum86 and eccrine gland-derived products, such as 
lactic acid87. In atopic eczematous lesions, the epidermal permeability barrier is 
perturbed and the skin pH is also significantly elevated88. In addition to the 
perturbation of lipid metabolism and their molecular organization, increased 
skin pH also induces bacterial growth (e.g. Staphylococcus aureus). Diverse 
functions for this acid mantle have been suggested, one of the major ones being 
antimicrobial action. A few studies relating surface pH and its role in supporting 
the growth of normal microflora as well as inhibiting skin pathogen growth 
have been previously reported89. A typical example where the impaired 
antimicrobial barrier is correlated with elevated skin surface pH is diaper 
dermatitis. Due to chronic exposure to urine and feces, diapered, neonatal skin 
shows a more neutral pH than uncovered skin90. In addition, pathogens that 
grow at neutral pH worsen diaper dermatitis91, resulting in a vicious cycle 
where neutral pH-enhanced pathogen growth and inflammatory cytokine 
release combine to produce an inflamed, colonized skin with impaired 
antimicrobial barriers92. Another important function of the acid mantle is related 
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to the extracellular processing of LB-derived lipid precursors, which comprise 
the SC intercellular lipid domain. Among the various important enzymes in SC 
are β-glucocerebrosidase, acid sphingomyelinase and sPLA2. Each of these 
functions optimally in an acidic environment and contributes to the generation 
of the ceramide molecules and free fatty acids required for epidermal 
permeability barrier homeostasis. Acute disruption of the permeability barrier 
results in a slight but significant increase in skin surface pH. Along with the 
barrier recovery, the acid mantle reappears. Recent reports using super-acid or 
super-base, which could modulate skin surface pH without affecting viable 
epidermis, also showed that skin surface pH regulated the epidermal barrier 
homeostasis57. In addition, maintenance of intact murine SC to a neutral pH 
produced significant abnormalities in SC integrity and cohesiveness93. Using 
neonatal hairless mice, Fluhr et al. showed that topical application of liver X 
receptor (LXR) activators accelerated SC acidification, as well as stimulated 
keratinocyte differentiation and improved permeability barrier homeostasis94. 
Among the proposed acidification pathways, LXR activators induced the 
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increase of sPLA2 activity in the SC. The above described roles of the SC acid 
mantle in epidermal permeability barrier function suggest that both barriers are 
closely related and maintenance of skin surface pH in the normal acidic range is 
crucial for not only the antimicrobial barrier, but epidermal permeability barrier 
function as well. Skin surface pH also affects the desquamation processes. A lot 
of protein degrading enzymes and proteases exist in the SC and each protease 
has its optimal pH, respectively95, 96. Since each protease has its own substrate 
in the corneodesmosome components, changes in pH induce abnormal 
desquamation and results in a scaly skin. A typical example of abnormal 
desquamation induced by alkaline pH is soap-induced xerotic skin97.  
  Blocking the proteolytic activities of allergens by either using a serine-
protease inhibitor or controlling pH resulted in normalized barrier recovery, 
which suggests that proteolytic activity primarily mediates the inhibitory effects 
of allergens on barrier function. Since the first localization of PAR-2 in 
epidermis, various cellular responses induced by PAR-2 activation, including 
inflammation and itching have been reported. A previous study showed that, in 
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human umbilical vein endothelial cell, activation of PAR-2 was induced by 
inflammatory mediators, such as tumor necrosis factor-α, interleukin-1α and 
bacterial lipopolysaccharide7. Using PAR-2-deficient mice, it was also shown 
that activation of PAR-2 by agonist peptide induced a reduction of leukocyte 
rolling velocity, increased leukocyte rolling flux, and increased leukocyte 
adhesion in endothelial tissue, all of which suggest an important role of PAR-2 
activation in the induction of inflammatory responses7. In skin, involvement of 
PAR-2 in type IV allergic dermatitis was suggested by a PAR-2-deficient mouse 
model98. Recently, it was also observed that PAR-2 stimulation in keratinocyte 
induced the activation of nuclear factor kappa B and upregulated intercellular 
cell adhesion molecule-1 mRNA99.  
  In addition to inflammation, PAR-2 is also known to be involved in 
neurogenic inflammation and in itching perception in skin. A large proportion 
of primary spinal afferent neurons expresses PAR-2 and also contains 
proinflammatory neuropeptide Substance P (SP) and calcitonin gene-related 
peptide (CGRP). Activation of PAR-2 in primary spinal afferent neurons results 
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in the release of SP and CGRP, which together induce neurogenic 
inflammation100. Atopic skin lesions are associated with increased release of 
tryptase in the skin and an upregulation of PAR-2 in nerve cells, and cutaneous 
administration of APs to these patients results in prolonged itching, even with 
antihistamine drugs101. These results suggest that PAR-2 is crucial in 
progression of skin inflammation and itching, and prevention of PAR-2 
activation by specific PAR-2 antagonist or protease inhibitors can be a 
promising therapeutic application for inflammatory and pruritic diseases102.  
  Activation of PAR-2 results in diverse cellular responses, including cell 
proliferation, differentiation, and production and release of proinflammatory 
cytokines. Increase of intracellular calcium ion concentration, through the 
generation of inositol 1,4,5-trisphosphate and diacylglycerol, is also induced by 
PAR-2 activation103. It is well known that in normal epidermis calcium ion 
distribution is uneven, and this epidermal calcium gradient plays a critical role 
in barrier function homeostasis. The loss of calcium gradient following barrier 
disruption induces the secretion and synthesis of lamellar bodies in the 
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epidermis. However, previous studies have shown that the calcium ion influx 
into the granulocyte after barrier disruption retarded the normal barrier lamellar 
body secretion and barrier repair processes36. A critical role for an epidermal 
calcium gradient in permeability barrier homeostasis is also suggested by the 
observations that modulation of the calcium gradient, without compromising 
permeability barrier function, could induce secretion and synthesis of lamellar 
bodies40, 47. Activation of PAR-2 by cockroach allergens resulted in an increase 
of intracellular calcium concentration in cultured human keratinocytes, and the 
inhibitory effects of these allergens on skin barrier function is in part due to this 
modulation of calcium ion concentration. Calcium-ion capture cytochemical 
staining showed increased calcium ion deposition in the granular layer after 
barrier disruption in allergens-applied skin, which confirmed this hypothesis. 
  Our results suggest that, along with the allergenic effects of HDM and 
cockroach allergens in AD, the proteolytic activities of both allergens can also 
affect permeability barrier homeostasis. In addition, an increase in skin pH, 
which also upregulates the proteolytic activity of aeroallergens investigated in 
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this study, is also observed in AD skin lesions104, 105. Diverse proteolytic 
enzymes such as kallikrein 7 (stratum corneum chymotryptic enzyme) and 
kallikrein 5 (stratum corneum tryptic enzyme), and protease inhibitors, such as 
lymphoepithelial Kazal-type related inhibitor, exist in normal stratum corneum, 
and the balance between degradation and protection of corneodesmosome 
proteins determines the desquamation process. Previous reports, however, also 
suggested an involvement of the kallikrein proteases in the pathogenesis of 
inflammatory skin diseases, such as AD. Increased expression of kallikrein 
mRNA and proteins were observed in AD skin lesions106 and, using a transgenic 
mouse model, it was also shown that increased kallikrein 7 activity in 
suprabasal keratinocyte induced pathologic skin changes, such as increased 
epidermal skin thickness, hyperkeratosis, dermal inflammation, and severe 
pruritis107. The importance of increased protease activity in AD skin lesions is 
also supported by the observation that protease inhibitor expression is lowered 
in AD skin. The serine protease inhibitor LEKTI is a potent inhibitor of both 
kallikrein 5 and kallikrein 7108, and a defect in the serine protease inhibitor 
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Kazal-type 5 (SPINK5) gene, encoding LEKTI, has been reported in AD 
patients109, 110. These results support the hypothesis that increased protease 
activity is an important pathophysiologic factor for inflammatory skin disease. 
Changing the epidermal permeability barrier homeostasis has recently been 
proposed as one of several possible mechanisms by which proteases are 
involved in AD skin lesions. Denda et al. reported that topical application of the 
protease inhibitor trans-4-(aminomethyl)cyclohexane carboxylic acid (t-
AMCHA) to barrier-disrupted skin accelerated barrier recovery in murine and 
human skin111. In addition, it was also reported that neutralization of SC 
resulted in functional abnormalities of SC, as well as aberrant permeability 
barrier homeostasis due to the excessive degradation of corneodesmosome112 
and lipid processing enzymes in SC113. A progressive degradation of epithelial 
tight junction proteins by the protease activities in house dust HDM allergens 
was also previously reported114, 115. While it needs to be investigated whether 
HDM or cockroach allergens can also degrade corneodesmosome or lipid 
processing enzymes in SC, these studies suggest that both allergens can induce 
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abnormalities in SC integrity, as well as the epidermal permeability barrier 
function, even in normal skin (Fig 9). 
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Figure 9. Involvement of mite allergens and cockroach allergens in 
epidermal permeability barrier homeostasis. (GCE: German cockroach 
extract, DME: Dust mite extract) (Black line: stimulating, Red line: 
inhibition) 
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V. CONCLUSION 
In conclusion, PAR-2 in epidermis functions in skin barrier homeostasis and 
activation of PAR-2 by aeroallergens results in significant delay in barrier 
recovery. The inhibitory effects of aeroallergens could be overcome by either 
co-application of protease inhibitor or maintaining skin pH at its normal acidic 
range. Since the perturbation in epidermal permeability barrier function is one 
of the most important pathophysiologic factors in AD, our results suggest that 
aeroallergens not only induce the allergic reactions, but also interfere with the 
barrier homeostatic responses in AD skin lesions. These results thus provide the 
possibility that application of protease or PAR-2 inhibitors or skin pH 
maintenance may be of therapeutic value for AD skin lesions. 
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국문 요약 
 
표피 투과 장벽에서 protease-activated receptor 2의 역할에 대한 연구 
 
<지도교수 이승헌> 
 
연세대학교 대학원 의과학과 
정세규 
 
 Protease-activated receptor (PAR)는 G-단백질 수용체의 일종으로서, 
세포막 외부에 존재하는 특정한 펩타이드 서열이 단백질 분해효소에 
의하여 절단되면서 나타나는 활성화 펩타이드에 의하여 스스로 
활성화되는 독특한 기전을 나타내는 수용체이다. 최근, 동물 모델을 
이용한 실험을 통하여 이러한 PAR-2 수용체가 표피투과장벽의 
항상성 유지에 중요한 역할을 하며, 특히 PAR-2 수용체에 대한 
활성화제가 급성투과장벽 손상 후 회복과정을 지연하는 것이 보고된 
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바 있다. 또한, 아토피 피부염 병변에서 단백질 분해효소의 활성이 
정상 피부에 비하여 매우 높아져 있다는 점에서, 이렇게 증가된 
단백질 분해효소에 의한 PAR-2 수용체의 활성화가 아토피 피부염의 
병인으로서 작용할 수 있다는 가설이 제시되고 있다. 바퀴벌레나 
진드기 유래의 알레르겐은 천식이나 알레르기성 비염, 아토피 
피부염과 같은 알레르기성 질환과 밀접하게 연관되어 있으며, 최근의 
연구 결과에 따르면 이러한 알레르겐이 PAR-2 수용체를 활성화하는 
것으로 보고되고 있다. 따라서 본 연구에서는 바퀴벌레와 진드기 
알레르겐이 표피투과장벽에 미치는 영향과 표피 내 칼슘 이온 
기울기에 미치는 영향을 관찰하고자 하였다. 표피투과장벽을 급격히 
손상시킨 후 알레르겐을 도포한 결과, 정상인의 피부와 동물 
모델에서 경피수분손실의 회복이 저해되었다. 또한, 알레르겐을 
피부에 도포한 경우, 표피 내 단백질 분해효소의 활성이 증가되는 
소견도 관찰되었으며, 전자 현미경 소견 상 과립층과 각질층 간 
층판소체의 분비가 저해되었다. PAR-2 수용체에 대한 저해제를 
이용한 실험 결과, 알레르겐이 경피투과장벽에 미치는 효과가 PAR-2 
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수용체의 활성화에 의한 것임을 확인할 수 있었다. 또한, 단백질 
분해효소의 저해제를 이용하거나, 각질층의 pH를 낮춤으로서 이러한 
알레르겐의 효과를 억제할 수 있음을 관찰하였다. 배양된 
각질형성세포를 이용한 실험 결과, 알레르겐이 세포 내 칼슘 이온의 
농도를 증가시키는 것을 관찰하였고, 이러한 세포 내 칼슘 이온의 
변화는 동물 모델에서 표피 내 칼슘 이온 기울기의 변화를 
관찰함으로써 in vivo에서도 동일하게 나타났다.  
이상의 결과에 의하면, 바퀴벌레나 진드기에서 유래한 알레르겐은 
표피 내 PAR-2 수용체를 활성화하고, 표피 내 칼슘 이온 기울기를 
변화시킴으로써 표피투과장벽에 영향을 주는 것으로 사료된다. 또한, 
단백질 분해효소의 저해제를 동시에 도포하거나, 각질층의 pH 조절 
및 PAR-2 수용체에 대한 저해제는 알레르겐의 효과를 억제하였다.  
 
핵심되는 말: 부유 알레르겐, 표피 내 칼슘 이온 기울기, Protease-
activated receptor-2, PAR-2 저해제, 피부 장벽 
 
